The positive Phase 2 data and extended cash runway support near-term clinical execution, but profitability remains distant. Traders should monitor progress toward the NS002 pivotal trial initiation in Q4 2026 and any regulatory feedback. The $15 million financing significantly de-risks the near-term path but adds potential dilution concerns if future offerings are needed.
Price Chart
Executive Summary
Nasus Pharma released its 2025 annual results and provided a business update, highlighting positive Phase 2 data for its intranasal epinephrine candidate NS002, a strengthened cash position of $4.3 million following its IPO and a $15 million private placement, and plans to initiate a pivotal study for NS002 in Q4 2026. The company also advanced its early-stage pipeline, though it reported a widening net loss of $5.9 million in 2025.
Key Facts
- Positive Phase 2 results for NS002 showed statistically significant improvements in early epinephrine absorption compared to EpiPen®.
- Pivotal study for NS002 planned for Q4 2026, with readout expected Q1 2027.
- Cash, cash equivalents, and marketable securities totaled $4.3 million as of December 31, 2025, up from $0.3 million in 2024.
- Company secured $15 million in private placement in February 2026, extending cash runway into Q2 2027.
- Net loss increased to $5.9 million in 2025 from $1.5 million in 2024, driven by higher R&D and G&A expenses.
- First-in-human studies for NS003 and NS004 expected in second half of 2026.
Financial Impact
Cash position increased by $4 million YoY; $15 million follow-on financing secured. Net loss widened by $4.4 million. R&D and G&A expenses rose significantly due to clinical development and public company costs.
Risk Factors
- Clinical development risk: Pivotal trial for NS002 may not replicate Phase 2 results.
- Dilution risk: Future capital raises may be necessary beyond Q2 2027, impacting shareholders.
- Competition: EpiPen® and other epinephrine auto-injectors dominate the market.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3262206 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 18d ago | 6-K | $3.51 | awaiting T+20 | — | $3.49 (−0.57%) |
Sep 23, 2026 4w ago | 3 | $3.64 $3.06 | ▼ −15.93% | ▼ −16.62% | $3.49 (−4.12%) |
Sep 18, 2026 5w ago | 424B5 | $3.44 $3.21 | ▲ +6.83% | ▲ +5.92% | $3.49 (−1.45%) |
Sep 14, 2026 6w ago | 6-K | $3.65 $3.32 | ▼ −9.04% | ▼ −11.30% | $3.49 (−4.38%) |
Sep 14, 2026 6w ago | EFFECT | $3.65 $3.32 | ▼ −9.04% | ▼ −11.30% | $3.49 (−4.38%) |
Aug 21, 2026 9w ago | EFFECT | $4.00 $3.44 | ▼ −14.00% | ▼ −13.47% | $3.49 (−12.75%) |
Aug 19, 2026 9w ago | 6-K | $3.84 $3.53 | ▼ −8.07% | ▼ −6.12% | $3.49 (−9.11%) |
Aug 17, 2026 10w ago | 6-K | $3.70 $3.59 | ▼ −2.97% | ▼ −1.00% | $3.49 (−5.68%) |
Aug 17, 2026 10w ago | Press Release | $3.70 $3.59 | ▼ −2.97% | ▼ −1.00% | $3.49 (−5.68%) |
Apr 1, 2026 29w ago | EFFECT | $2.55 $2.56 | ▼ −0.39% | ▲ +9.33% | $3.49 (−36.86%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers